Director Shareholding

RNS Number:7832J
GW Pharmaceuticals PLC
11 September 2001


                                 SCHEDULE 11

         NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS


 1. Name of Company

    GW Pharmaceuticals plc

 2. Name of Director

    David Kirk

 3. Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
    non-beneficial interest or in the case of an individual holder if it is a
    holding of that person's spouse or children under the age of 18 or in
    respect of a non-beneficial interest

    As in 2 above

 4. Name of the registered holder(s) and, if more than one holder, the number
    of shares held by each of them (if notified)





 5. Please state whether notification relates to a person(s) connected with the
    Director named in 2 above and identify the connected person(s)





 6. Please state the nature of the transaction. For PEP transactions please
    indicate whether general/single co PEP and if discretionary/non
    discretionary





 7. Number of shares/amount of stock acquired





 8. Percentage of issued class





 9. Number of shares/amount of stock disposed





10. Percentage of issued class





11. Class of security





12. Price per share





13. Date of transaction





14. Date company informed





15. Total holding following this notification





16. Total percentage holding of issued class following this notification





    If a director has been granted options by the company please complete the
    following boxes

17. Date of grant

    10th September 2001

18. Period during which or date on which exercisable

    11th September 2004 - 10th September 2011

19. Total amount paid (if any) for grant of the option

    N/A

20. Description of shares or debentures involved: class, number

    Ordinary Shares of 0.1p each

21. Exercise price (if fixed at time of grant) or indication that price is to
    be fixed at time of exercise

    104.5p per share

22. Total number of shares or debentures over which options held following
    this notification

    900,000

23. Any additional information

    Options over 28,708 Ordinary Shares granted pursuant to GW Pharmaceuticals
    Approved Share Option Scheme

    Options over 871,292 Ordinary Shares granted pursuant to GW
    Pharmaceuticals Executive Share Option Scheme.

24. Name of contact and telephone number for queries

    Jonathan Laughton, [phone]



25. Name and signature of authorised company official responsible for making
    this notification



Jonathan Laughton, Company Secretary



Date of Notification: 11th September 2001